Allokraft - HotSpot Therapeutics
March 17, 2026
Balancing the Risks and Rewards of Drug Development in China: A Small Biotech CEO Perspective
Of the recurring themes that tend to circulate in the drug development discourse, China is a uniquely fascinating and polarizing...
by Jonathan Montagu
November 13, 2025
A CEO’s Perspective on Navigating Choppy Market Waters
I’m far from the first person to point out the prolonged market challenges that have depressed the biotech fundraising environment...
by Jonathan Montagu
July 31, 2025
A “Complex” Solution to a “Complex” Problem? Attacking KRASG12X Colorectal Cancer Through the CBM Signalosome
As scientists, we are accustomed to learning something new about targets (and the modulation thereof) that moves the field forward...
by Geraldine Harriman
February 5, 2025
A New Wave of Therapeutic Innovation Through Targeting Transcription Factors
In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one...
by Jonathan Montagu
October 10, 2024
ESMO Reflections: Glimmers of Hope with the Next Wave of I-O Therapies?
HotSpot’s trip to Barcelona for the recent European Society of Medical Oncology (ESMO) Annual Meeting was no ‘European Vacation,’ but...
by Jonathan Montagu
May 9, 2024
Has Spring Sprouted New Growth in Immuno-Oncology?
As Boston’s weather has started its turn from the frigid darkness that is a northeast winter to the longer days...
by Jonathan Montagu
February 7, 2024
Drug Discovery: Taking Inspiration from Facial Recognition
At HotSpot, we’re harnessing insights from nature by pinpointing specialized protein on/off switches, or pockets, called “natural hotspots.” To date,...
by Geraldine Harriman
January 3, 2024
Signaling Complexes: A Ripe Opportunity for Drug Development
Signaling pathways are the intricate networks that govern cell behavior, lying at the crux of cell function. They are used...
by Jonathan Montagu
July 11, 2023
On the Road at ASCO 2023: Key Takeaways, Observations and Reflections
The American Cancer Society for Oncology (ASCO) annual meeting is among the highlights of the clinical oncology calendar. The meeting...
by Amanda Redig
June 1, 2023
How We Balance the What and How at HotSpot
At HotSpot, we are committed to building something we believe is truly distinctive, setting ourselves apart from our peers in...
by Jonathan Montagu
April 28, 2023
Moving Our Core Values Beyond Table Stakes
Every company has a culture, either by design or default. From our inception in 2016, we wanted to create a...
by Jonathan Montagu
March 1, 2023
Build It and They Will Come – New Review Spotlights the Scientific Momentum Building for CBL-B Inhibition
The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more...
by Jonathan Montagu
January 4, 2023
Reimagining I-O with Our First Investigational Drug and a New Approach to Clinical Discovery
HotSpot Therapeutics recently announced FDA clearance of our Investigational New Drug (IND) application for HST-1011, our small molecule allosteric inhibitor...
by Jonathan Montagu
December 6, 2022
What Took So Long? – How Tech Has Finally Caught Up with Transcription Factors
HotSpot Therapeutics recently announced a strategic collaboration with AbbVie to develop IRF5 transcription factor inhibitors for autoimmune diseases. The following…
by Geraldine Harriman
November 10, 2022
A Turning Point for Immuno-Oncology
Immunotherapy has been the holy grail in the fight against cancer for the last decade. For good reason, we’ve been...
by Tim Reilly
June 21, 2022
Hacking the Human Cell – How Once ‘Un-druggable’ Proteins Became the New Frontier in Drug Development
White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system...
by Jonathan Montagu
April 28, 2022
A Global Community
It is in moments like this that we are reminded of the collective power of good to overcome the disenfranchised…
by Jonathan Montagu
March 8, 2022
Staying Human in the Age of Artificial Intelligence
No, your next doctor will not be a robot. Nor will an algorithm cure cancer. However, AI technology will absolutely...
by Ramy Farid and Jonathan Montagu
January 10, 2022
Making R&D ‘Smarter’ by Putting Artificial Intelligence into Practice
The pharmaceutical industry still faces unrelenting challenges across the entirety of the drug development landscape. According to Piper Sandler’s recent...
by Geraldine Harriman and Tim Reilly
November 29, 2021
Hitting the Spot
Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing. This infusion of...
by Jonathan Montagu
July 13, 2021
Immuno-Oncology: The Comeback Kid
Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011...
by Tim Reilly
April 15, 2021
Reimagining the Workplace Post Pandemic
Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace
by Jonathan Montagu
May 20, 2020
The Business of Science
Today marks an important milestone for HotSpot Therapeutics as we announce our Series B financing, but it also marks a...
by Jonathan Montagu
August 23, 2019
Hotspots meet DNA-encoded libraries
DNA encoded libraries (DEL) have received a lot of attention over the past few years. They’ve been hailed as “highly...
by Geraldine Harriman
July 31, 2019
Targeting the mTORC1 Pathway With Phenotypic Screening
The conventional approach to drug discovery shines a light on specific target proteins, using an arsenal of biochemical and virtual...
by Jonathan Montagu
June 30, 2019
Biocentury Innovations shines a new light on allostery
I was excited to participate in Allison Johnson’s recent Biocentury article reflecting on the growing interest of industry in allostery and why...
by Geraldine Harriman
May 1, 2019
Drugging the Undruggable with Allosteric Small Molecules
Advances in computational, biophysical and library technologies have driven the emergence of a new drug discovery paradigm with the power...
by Nicholas Keen
April 9, 2019
Cats and the future of machine learning in drug discovery
The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that not everyone is...
by Jonathan Montagu
March 11, 2019
HotSpot Frequently Asked Questions
What is a regulatory hotspot? A regulatory hotspot is a privileged allosteric site used by nature to regulate the function...
by Geraldine Harriman
March 4, 2019
Introducing allokraft
This is an exciting time for small molecule drug discovery and soon for patients, who have been underserved by current...
by Jonathan Montagu
January 4, 2019
Following Nature’s lead
Lately it seems that allostery is constantly in the news, especially in stories covering a series of high-profile financings by...
by Jonathan Montagu
July 17, 2018
Hotspot Therapeutics Turns Up The Heat On Natural Allostery
Most conventional small molecule drugs engage directly with the engine of a protein’s function, aiming to often turning off an...
by Bruce Booth
June 13, 2018
Float Like A Butterfly: Agility In Biotech
In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations. This...
by Jonathan Montagu
March 5, 2018
Allostery: Realizing the promise
It starts off with flu-like symptoms and progresses to a perpetual low-grade fever, excessive sweating and loss of appetite. A...
by Jonathan Montagu